Table 1 Patient Characteristics.
From: Influence of H7N9 virus infection and associated treatment on human gut microbiota
Patient No. | Age | Sex | Antibiotic treatment | Antiviral treatment | Probiotics given | TPF-D given | BMI | Outcomes |
|---|---|---|---|---|---|---|---|---|
1 | 79 | M | Piperacillin-sulbactam, imipenem-cilastatin | Oseltamivir | Clostridium tablets, Bacillus capsules | Yes | 27.1 | Outpatient |
2 | 55 | F | Piperacillin-sulbactam, piperacillin-tazobactam | Oseltamivir | Clostridium tablets | No | 27.7 | Outpatient |
3 | 68 | M | Piperacillin-tazobactam, vancomycin, imipenem-cilastatin, | Oseltamivir | Clostridium tablets | Yes | 23.0 | Outpatient |
4 | 38 | M | Vancomycin, piperacillin-tazobactam, | Oseltamivir | Clostridium tablets | Yes | 22.7 | Outpatient |
5 | 43 | M | None | Oseltamivir | Clostridium tablets | No | 23.2 | Outpatient |
6 | 57 | M | None | Oseltamivir | Clostridium tablets | No | 18.8 | Outpatient |
7 | 75 | M | Sulbactam-cefoperazone, moxifloxacin, piperacillin-tazobactam | Oseltamivir | Clostridium tablets | No | 22.7 | Outpatient |
8 | 66 | M | Piperacillin-tazobactam, imipenem-cilastatin, sulbactam-cefoperazone | Oseltamivir | Clostridium tablets | Yes | 29.8 | Outpatient |
9 | 80 | F | Fluconazole, piperacillin-tazobactam, | Oseltamivir | Clostridium tablets | No | 21.1 | Outpatient |
10 | 59 | F | None | Oseltamivir | Clostridium tablets, B. Subtilis and E. faecium enteric coated capsules | No | 25.4 | Outpatient |
11 | 55 | M | None | Oseltamivir | B. Subtilis and E. faecium enteric coated capsules | No | 21.3 | Outpatient |
12 | 58 | M | Piperacillin-sulbactam | Oseltamivir | None | No | 23.4 | Outpatient |
13 | 65 | M | None | Oseltamivir | Clostridium tablets | No | 22.9 | Outpatient |
14 | 63 | M | Fluconazole, piperacillin-tazobactam, moxifloxacin | Oseltamivir | Clostridium tablets | No | 24.2 | Outpatient |
15 | 30 | M | Piperacillin-tazobactam, moxifloxacin | Oseltamivir | Clostridium tablets, B. Subtilis and E. faecium enteric coated capsules | No | 26.0 | Outpatient |
16 | 48 | M | Moxifloxacin | Oseltamivir | Clostridium tablets | No | 26.0 | Outpatient |
17 | 38 | M | Moxifloxacin | Oseltamivir | Clostridium tablets | No | 23.2 | Outpatient |
18 | 33 | F | Moxifloxacin | Oseltamivir | Clostridium tablets | No | 20.8 | Outpatient |
19 | 67 | M | Moxifloxacin, vancomycin, piperacillin-tazobactam | Oseltamivir | Clostridium tablets | Yes | 26.0 | Died |
20 | 73 | F | Moxifloxacin, vancomycin, tigecycline, piperacillin-tazobactam, sulbactam-cefoperazone, | Oseltamivir | Clostridium tablets | Yes | 25.1 | Died |
21 | 75 | M | Moxifloxacin, vancomycin, piperacillin-tazobactam, sulbactam- cefoperazone | Oseltamivir | Clostridium tablets | Yes | 25.3 | Outpatient |
22 | 68 | F | None | Oseltamivir | Clostridium tablets | No | 25.7 | Outpatient |
23 | 41 | M | None | Oseltamivir | Clostridium tablets | No | 19.4 | Outpatient |
24 | 37 | F | None | Oseltamivir | Clostridium tablets | No | 27.3 | Outpatient |
25 | 80 | M | Levofloxacin, piperacillin-tazobactam | Oseltamivir | Clostridium tablets | No | 22.6 | Outpatient |
26 | 39 | M | None | Oseltamivir | Clostridium tablets | No | 20.1 | Outpatient |
